Key result
Implantation of an epicardial biomaterial graft in a rat model of ischemic cardiomyopathy prolonged ventricular effective refractory period without changing VT incidence.
Why the study?
Patients with HFrEF are at increased risk of VT and ventricular fibrillation, and it was hypothesized that myocardial refractoriness could be surgically modulated to reduce VT susceptibility.
Does an epicardial biomaterial graft containing human dermal fibroblasts prolong ventricular ERP and reduce VT susceptibility in a rat model of HFrEF?
Does an epicardial biomaterial graft containing human dermal fibroblasts prolong ventricular ERP and reduce VT susceptibility in a rat model of HFrEF?
Surgical deployment of a fibroblast-containing biomaterial prolonged ventricular ERP in a rodent ischemic cardiomyopathy model, though it did not significantly reduce VT incidence.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for surgical modulation of refractoriness in HFrEF; larger trials needed before clinical consideration.
Patients diagnosed with heart failure with reduced ejection fraction (HFrEF) are at increased risk of monomorphic ventricular tachycardia (VT) and ventricular fibrillation. The presence of myocardial fibrosis provides both anatomical and functional barriers that promote arrhythmias in these patients. Propagation of VT in a reentrant circuit depends on the presence of excitable myocardium and the refractoriness of the circuit. We hypothesize that myocardial refractoriness can be modulated surgically in a model of HFrEF, leading to decreased susceptibility to VT.Male Sprague-Dawley rats were infarcted via permanent left coronary artery ligation. At 3 weeks post-infarction, engineered grafts composed of human dermal fibroblasts cultured into a polyglactin-910 biomaterial were implanted onto the epicardium to cover the area of infarction. Three weeks post-graft treatment, all rats underwent a terminal electrophysiologic study to compare monophasic action potential electroanatomic maps and susceptibility to inducible monomorphic VT.HFrEF rats (n=29) demonstrated a longer (p=0.0191) ventricular effective refractory period (ERP) and a greater (p=0.0394) VT inducibility compared with sham (n=7). HFrEF rats treated with the graft (n=12) exhibited no change in capture threshold (p=0.3220), but had a longer ventricular ERP (p=0.0029) compared with HFrEF. No statistically significant change in VT incidence was found between HFrEF rats treated with the graft and untreated HFrEF rats (p=0.0834).Surgical deployment of a fibroblast-containing biomaterial in a rodent ischemic cardiomyopathy model prolonged ventricular ERP as measured by programmed electrical stimulation. This hypothesis-generating study warrants additional studies to further characterize the antiarrhythmic or proarrhythmic effects of this novel surgical therapy.
No takes yet. Share an insight, caveat, or question.
Chinyere et al. (2020) studied Ischemic cardiomyopathy / Heart failure with reduced ejection fraction (n=36). Epicardial biomaterial graft (human dermal fibroblasts in polyglactin-910) vs. Untreated HFrEF rats was evaluated on Ventricular effective refractory period (ERP) and VT incidence (p=0.0029). Implantation of an epicardial biomaterial graft in a rat model of ischemic cardiomyopathy prolonged ventricular effective refractory period without changing VT incidence.
Synapse has enriched 10 related papers. Consider them for comparative context: